指南与共识母胎医学产科

SMFM咨询系列#57:孕中期孤立性软指标评估与管理

Society for Maternal-Fetal Medicine Consult Series #57: Evaluation and management of isolated soft ultrasound markers for aneuploidy in the second trimester: (Replaces Consults #10, Single umbilical artery, October 2010; #16, Isolated echogenic bowel diagnosed on second-trimester ultrasound, August 2011; #17, Evaluation and management of isolated renal pelviectasis on second-trimester ultrasound,
指南 / 共识 · Am J Obstet Gynecol · 2021-06-23

该指南由母胎医学会制定,针对孕中期超声发现的孤立性软指标,在现有血清学筛查和无创DNA筛查背景下提出评估与管理建议。指南强调筛查阴性后孤立软指标不应仅因此行诊断性检查,并针对不同软指标给出分层管理方案(GRADE 1B/1C)。

要点

  • 筛查阴性后孤立软指标不推荐仅因软指标行诊断性检查(1B)。
  • 无既往筛查者依软指标类型选择无创筛查或诊断性检查。
  • 孤立性强回声肠管需评估囊性纤维化和巨细胞病毒。

核心结论

  • 血清学或cfDNA筛查阴性后,孤立软指标不推荐仅因此行诊断性检查(1B)。
  • 无既往筛查者应根据软指标类型选择无创筛查或诊断性检查(1B/1C)。

研究设计与样本

  • 母胎医学会(SMFM)制定的临床指南,替代既往3个咨询文件。

主要发现

  • 孤立性心内强回声灶筛查阴性后无需进一步评估(1B)。
  • 孤立性强回声肠管需评估囊性纤维化和胎儿巨细胞病毒感染(1C)。
  • 孤立性单脐动脉无需额外非整倍体评估,建议晚孕期超声评估生长(1C)。

关键数值与推荐

  • 筛查阴性后孤立心内强回声灶无需胎儿超声心动图、随访超声或生后评估(1B)。
  • 孤立性鼻骨缺失/发育不良且筛查阴性者,血清学筛查阴性可讨论cfDNA或羊膜腔穿刺(1B),cfDNA阴性则无需进一步评估(1B)。
  • 孤立性脉络丛囊肿筛查阴性后无需进一步评估(1C)。

临床怎么用

  • 对筛查阴性孕妇,孤立软指标不常规行羊膜腔穿刺。
  • 无既往筛查者应提供cfDNA或四联筛查,必要时讨论诊断性检查。
  • 孤立性强回声肠管需查囊性纤维化和巨细胞病毒,并晚孕期超声随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Soft markers were originally introduced to prenatal ultrasonography to improve the detection of trisomy 21 over that achievable with age-based and serum screening strategies. As prenatal genetic screening strategies have greatly evolved in the last 2 decades, the relative importance of soft markers has shifted. The purpose of this document is to discuss the recommended evaluation and management of isolated soft markers in the context of current maternal serum screening and cell-free DNA screening options. In this document, "isolated" is used to describe a soft marker that has been identified in the absence of any fetal structural anomaly, growth restriction, or additional soft marker following a detailed obstetrical ultrasound examination. In this document, "serum screening methods" refers to all maternal screening strategies, including first-trimester screen, integrated screen, sequential screen, contingent screen, or quad screen. The Society for Maternal-Fetal Medicine recommends the following approach to the evaluation and management of isolated soft markers: (1) we do not recommend diagnostic testing for aneuploidy solely for the evaluation of an isolated soft marker following a negative serum or cell-free DNA screening result (GRADE 1B); (2) for pregnant people with no previous aneuploidy screening and isolated echogenic intracardiac focus, echogenic bowel, urinary tract dilation, or shortened humerus, femur, or both, we recommend counseling to estimate the probability of trisomy 21 and a discussion of options for noninvasive aneuploidy screening with cell-free DNA or quad screen if cell-free DNA is unavailable or cost-prohibitive (GRADE 1B); (3) for pregnant people with no previous aneuploidy screening and isolated thickened nuchal fold or isolated absent or hypoplastic nasal bone, we recommend counseling to estimate the probability of trisomy 21 and a discussion of options for noninvasive aneuploidy screening through cell-free DNA or quad screen if cell-free DNA is unavailable or cost-prohibitive or diagnostic testing via amniocentesis, depending on clinical circumstances and patient preference (GRADE 1B); (4) for pregnant people with no previous aneuploidy screening and isolated choroid plexus cysts, we recommend counseling to estimate the probability of trisomy 18 and a discussion of options for noninvasive aneuploidy screening with cell-free DNA or quad screen if cell-free DNA is unavailable or cost-prohibitive (GRADE 1C); (5) for pregnant people with negative serum or cell-free DNA screening results and an isolated echogenic intracardiac focus, we recommend no further evaluation as this finding is a normal variant of no clinical importance with no indication for fetal echocardiography, follow-up ultrasound imaging, or postnatal evaluation (GRADE 1B); (6) for pregnant people with negative serum or cell-free DNA screening results and isolated fetal echogenic bowel, urinary tract dilation, or shortened humerus, femur, or both, we recommend no further aneuploidy evaluation (GRADE 1B); (7) for pregnant people with negative serum screening results and isolated thickened nuchal fold or absent or hypoplastic nasal bone, we recommend counseling to estimate the probability of trisomy 21 and discussion of options for no further aneuploidy evaluation, noninvasive aneuploidy screening through cell-free DNA, or diagnostic testing via amniocentesis, depending on clinical circumstances and patient preference (GRADE 1B); (8) for pregnant people with negative cell-free DNA screening results and isolated thickened nuchal fold or absent or hypoplastic nasal bone, we recommend no further aneuploidy evaluation (GRADE 1B); (9) for pregnant people with negative serum or cell-free DNA screening results and isolated choroid plexus cysts, we recommend no further aneuploidy evaluation, as this finding is a normal variant of no clinical importance with no indication for follow-up ultrasound imaging or postnatal evaluation (GRADE 1C); (10) for fetuses with isolated echogenic bowel, we recommend an evaluation for cystic fibrosis and fetal cytomegalovirus infection and a third-trimester ultrasound examination for reassessment and evaluation of growth (GRADE 1C); (11) for fetuses with an isolated single umbilical artery, we recommend no additional evaluation for aneuploidy, regardless of whether results of previous aneuploidy screening were low risk or testing was declined. We recommend a third-trimester ultrasound examination to evaluate growth and consideration of weekly antenatal fetal surveillance beginning at 36 0/7 weeks of gestation (GRADE 1C); (12) for fetuses with isolated urinary tract dilation A1, we recommend an ultrasound examination at ≥32 weeks of gestation to determine if postnatal pediatric urology or nephrology follow-up is needed. For fetuses with urinary tract dilation A2-3, we recommend an individualized follow-up ultrasound assessment with planned postnatal follow-up (GRADE 1C); (13) for fetuses with isolated shortened humerus, femur, or both, we recommend a third-trimester ultrasound examination for reassessment and evaluation of growth (GRADE 1C).

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Prabhu M, Kuller JA, Biggio JR, et al. Society for Maternal-Fetal Medicine Consult Series #57: Evaluation and management of isolated soft ultrasound markers for aneuploidy in the second trimester: (Replaces Consults #10, Single umbilical artery, October 2010; #16, Isolated echogenic bowel diagnosed on second-trimester ultrasound, August 2011; #17, Evaluation and management of isolated renal pelviectasis on second-trimester ultrasound, December 2011; #25, Isolated fetal choroid plexus cysts, April 2013; #27, Isolated echogenic intracardiac focus, August 2013). Am J Obstet Gynecol. 2021. PMID: 34171388. doi:10.1016/j.ajog.2021.06.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。